258 related articles for article (PubMed ID: 33949772)
1. Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial-to-mesenchymal transition, inflammation and angiogenesis.
Liu F; Yu C; Qin H; Zhang S; Fang L; Wang Y; Wang J; Cui B; Hu S; Liu N; Zhuang S
J Cell Mol Med; 2021 May; 25(13):6103-14. PubMed ID: 33949772
[TBL] [Abstract][Full Text] [Related]
2. Delayed Administration of Nintedanib Ameliorates Fibrosis Progression in CG-Induced Peritoneal Fibrosis Mouse Model.
Cui B; Yu C; Zhang S; Hou X; Wang Y; Wang J; Zhuang S; Liu F
Kidney Dis (Basel); 2022 Jul; 8(4):319-333. PubMed ID: 36157259
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis.
Xu L; Liu N; Gu H; Wang H; Shi Y; Ma X; Ma S; Ni J; Tao M; Qiu A; Zhuang S
Oncotarget; 2017 Oct; 8(51):88730-88750. PubMed ID: 29179471
[TBL] [Abstract][Full Text] [Related]
4. A protective role of nintedanib in peritoneal fibrosis through H19-EZH2-KLF2 axis via impeding mesothelial-to-mesenchymal transition.
Zhong W; Fu J; Liao J; Ouyang S; Yin W; Liang Y; Liu K
Int Urol Nephrol; 2024 Jun; 56(6):1987-1999. PubMed ID: 38097887
[TBL] [Abstract][Full Text] [Related]
5. Nitro-oleic acid inhibits the high glucose-induced epithelial-mesenchymal transition in peritoneal mesothelial cells and attenuates peritoneal fibrosis.
Su W; Wang H; Feng Z; Sun J
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F457-F467. PubMed ID: 31760768
[TBL] [Abstract][Full Text] [Related]
6. Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition.
Wang J; Wang L; Xu L; Shi Y; Liu F; Qi H; Liu N; Zhuang S
Oncotarget; 2017 Oct; 8(48):83872-83889. PubMed ID: 29137389
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.
Loureiro J; Sandoval P; del Peso G; Gónzalez-Mateo G; Fernández-Millara V; Santamaria B; Bajo MA; Sánchez-Tomero JA; Guerra-Azcona G; Selgas R; López-Cabrera M; Aguilera AI
PLoS One; 2013; 8(4):e61165. PubMed ID: 23637793
[TBL] [Abstract][Full Text] [Related]
8. Activated protein C inhibits mesothelial-to-mesenchymal transition in experimental peritoneal fibrosis.
Giri H; Biswas I; Rezaie AR
J Thromb Haemost; 2023 Jan; 21(1):133-144. PubMed ID: 36695376
[TBL] [Abstract][Full Text] [Related]
9. Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-β1/Smad3 signaling pathway.
Jiang N; Zhang Z; Shao X; Jing R; Wang C; Fang W; Mou S; Ni Z
J Cell Physiol; 2020 Jan; 235(1):364-379. PubMed ID: 31236971
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Liu F; Wang L; Qi H; Wang J; Wang Y; Jiang W; Xu L; Liu N; Zhuang S
Clin Sci (Lond); 2017 Aug; 131(16):2125-2143. PubMed ID: 28646122
[TBL] [Abstract][Full Text] [Related]
11. Delayed administration of suramin attenuates peritoneal fibrosis in rats.
Xiong C; Liu N; Shao X; Sharif S; Zou H; Zhuang S
BMC Nephrol; 2019 Nov; 20(1):411. PubMed ID: 31727005
[TBL] [Abstract][Full Text] [Related]
12. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Transglutaminase 2 Reduces Peritoneal Injury in a Chlorhexidine-Induced Peritoneal Fibrosis Model.
Kunoki S; Tatsukawa H; Sakai Y; Kinashi H; Kariya T; Suzuki Y; Mizuno M; Yamaguchi M; Sasakura H; Ikeno M; Takeuchi K; Ishimoto T; Hitomi K; Ito Y
Lab Invest; 2023 Apr; 103(4):100050. PubMed ID: 36870292
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway.
Li LF; Kao KC; Liu YY; Lin CW; Chen NH; Lee CS; Wang CW; Yang CT
J Cell Mol Med; 2017 Nov; 21(11):2937-2949. PubMed ID: 28598023
[TBL] [Abstract][Full Text] [Related]
15. Suramin inhibits the development and progression of peritoneal fibrosis.
Xiong C; Liu N; Fang L; Zhuang S; Yan H
J Pharmacol Exp Ther; 2014 Nov; 351(2):373-82. PubMed ID: 25168661
[TBL] [Abstract][Full Text] [Related]
16. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
17. Asiaticoside inhibits TGF-β1-induced mesothelial-mesenchymal transition and oxidative stress via the Nrf2/HO-1 signaling pathway in the human peritoneal mesothelial cell line HMrSV5.
Zhao J; Shi J; Shan Y; Yu M; Zhu X; Zhu Y; Liu L; Sheng M
Cell Mol Biol Lett; 2020; 25():33. PubMed ID: 32514269
[TBL] [Abstract][Full Text] [Related]
18. Functional molecules in mesothelial-to-mesenchymal transition revealed by transcriptome analyses.
Namvar S; Woolf AS; Zeef LA; Wilm T; Wilm B; Herrick SE
J Pathol; 2018 Aug; 245(4):491-501. PubMed ID: 29774544
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition.
Wilson RB; Archid R; Reymond MA
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32532126
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling.
Ueno T; Nakashima A; Doi S; Kawamoto T; Honda K; Yokoyama Y; Doi T; Higashi Y; Yorioka N; Kato Y; Kohno N; Masaki T
Kidney Int; 2013 Aug; 84(2):297-307. PubMed ID: 23486522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
